Will FDA eye-stroke warning put India's booming GLP-1 market on alert?

The FDA has ordered GLP-1 drug labels to flag a potential risk of NAION. The move sharpens scrutiny as cheaper weight-loss medicines reach more Indian patients. The US Food and Drug Administration has ordered safety labelling changes across the GLP-1 class, including the blockbuster diabetes and obesity medicines semaglutide and tirzepatide, to flag non-arteritic anterior ischaemic optic neuropathy (NAION). The condition is an “eye stroke”: blood flow to the front of the optic nerve is cut off, and sight in one eye can vanish overnight, painlessly and often for good. There is no proven treatment.The FDA’s analysis of 126 clinical trials covering over 134,000 participants found 6.4 NAION cases per 100,000 person-years among GLP-1 users, against 3.8 in comparison groups. That gap is under three cases per 100,000 patients a year.Endocrinologist Dr Sharwari Dabhade Dua of Fortis notes that the agency has identified a potential risk and has not established causation. “The absolute risk remains low, but the potential consequence is serious,” she said.The timing may have significance also in the Indian context, where these drugs have gone from rarity to routine in under two years. Lilly launched Mounjaro, which has tirzepatide as active ingredient, in March 2025, and Novo followed with Wegovy and Ozempic, with semagltude as active ingredient later. India’s anti-obesity drug sales jumped 115% in 2025, from Rs 571 crore to Rs 1,230 crore, driven largely by the new injectables.By October last year, Mounjaro had become the country’s top-selling medicine by value and has retained that position since.COURTS MOVED FIRST Regulators in Europe, Australia and Canada had already added NAION to product information, with the European Medicines Agency calling it a “very rare” effect of semaglutide. The FDA’s order extends the warning to the whole class in the world’s most influential drug market.The litigation had run ahead of the regulators. A 2024 study in JAMA Ophthalmology reported a sharply higher NAION hazard among semaglutide users, and it became the template for a wave of US lawsuits against Novo Nordisk and Eli Lilly.Since December 2025 the federal cases have sat in their own consolidated proceeding in Pennsylvania, with a parallel track in New Jersey. Both are in pretrial discovery.The central charge is failure to warn: that patients and doctors were never told. Both companies say the evidence does not establish the cause. A federal label change does not decide that dispute, but it gives plaintiffs a formal date on which the risk was recognised.GENERICS WIDEN THE NETIndia’s exposure grew again when semaglutide’s patent lapsed on March 20, 2026. More than 40 manufacturers rushed in with cheaper versions, and by June generics made up 82% of semaglutide unit sales. Novo has cut its own prices repeatedly.A drug that was a luxury just eighteen months ago is now within reach of a far wider population, including many who will never see a specialist.That is the worry of veteran diabetes specialist Dr Anoop Misra. He points to the “increasing and sometimes indiscriminate use” of these drugs, with cheap generics making it easier to start them without a proper medical evaluation.In his view they belong on a doctor’s prescription and under supervision, never as a cosmetic shortcut. The extra risk is a few cases per 100,000 patients a year, he says, small enough that benefits clearly win for most people with diabetes or obesity.WEIGHING THE RISKDoctors agree the answer is not to abandon the drugs. Dr Dua argueD for sharper screening and counselling instead. She says to give extra attention to patients with earlier NAION, existing optic nerve disease or several vascular risk factors. Diabetes, hypertension, high cholesterol, sleep apnoea and smoking already raise the odds of an eye stroke, and all are common in India.Dr Devendra Taneja, diabetologist with Shalby International Hospital in Gurugram summed up the evidence as “not conclusively proven”, though it still calls for “caution in every patient”.Dr Misra added that anyone with a past NAION episode should avoid these medicines altogether.Their advice on symptoms is consistent: sudden, painless blurring or loss of vision in one eye needs an eye specialist at once.Patients should not stop treatment on their own. Also, anyone diagnosed with NAION while on a GLP-1 drug should have their therapy reassessed with their doctor.The warning leaves the risk-benefit balance for most users where it was but what changes is accountability, experts underlined. Indian regulators and prescribers now have a US label to point to, and a market full of lightly supervised users to protect.- Ends